Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aim: To examine the impact of geriatric conditions and multimorbidity on the risk of incident disability and mortality among young-old and old-old adults.

Methods: The present study used nationally-representative data from the "Survey of Health and Living Status of the Elderly in Taiwan" for the years 2003 and 2007. Non-disabled older adults were divided into two age groups (65-79 years and ≥80 years). Chronic morbidities and geriatric conditions were assessed in 2003. Incident disability was defined as dependency in one or more activities of daily living in 2007. Vital statistics of the participants was linked to death registration data through 31 December 2007. Multivariable logistic regression and Cox regression were used to determine the effect of multimorbidity and geriatric conditions on health outcomes.

Results: Among those aged 65-79 years (n = 1874), the presentation of multimorbidity or two or more geriatric conditions was related to incident disability. Among octogenarians, the presentation of one or more geriatric conditions, but not multimorbidity, was shown to be independently associated with the risk of disability. Multimorbidity was related to a higher adjusted risk of mortality in the young-old group (hazard ratio 1.54; 95% confidence interval 1.1-2.2) but not in the old-old group. Among octogenarians, those with two or more geriatric conditions had a higher adjusted risk of mortality (hazard ratio 1.7; 95% confidence interval 1.2-2.5), compared with those with 0-1 geriatric conditions.

Conclusions: The risk of incident disability and mortality increased in octogenarians with geriatric conditions, but not in cases with multimorbidity.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ggi.12480DOI Listing

Publication Analysis

Top Keywords

geriatric conditions
32
incident disability
16
conditions multimorbidity
12
disability mortality
12
geriatric
9
risk incident
8
mortality young-old
8
65-79 years
8
multimorbidity geriatric
8
higher adjusted
8

Similar Publications

Dupilumab monotherapy in super-elderly patients with bullous pemphigoid: a retrospective study on long-term efficacy and safety in mild to moderate cases.

J Dermatolog Treat

December 2025

Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.

Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.

View Article and Find Full Text PDF

Patients with primary plasma cell leukemia (pPCL), particularly those with extramedullary disease (EMD), face a poor prognosis even with chimeric antigen receptor (CAR)-T cell therapy. This case report describes a patient with relapsed/refractory pPCL and life-threatening malignant pleural effusion (PE) treated with intrapleural CAR-T cells targeting B-cell maturation antigens. CAR-T cell expansion within the PE was observed, along with a rapid reduction in leukemia cell count and PE volume.

View Article and Find Full Text PDF

Glial fibrillary acidic protein (GFAP) is an astrocytic marker that can be assessed in blood using single molecule array technology. Recent studies suggest that individuals with posttraumatic stress disorder (PTSD) have suppressed circulating levels of this CNS biomarker. This study examined the hypothesis that PTSD and plasma GFAP levels share common genetic and epigenetic pathways.

View Article and Find Full Text PDF

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis.

Clin Lymphoma Myeloma Leuk

August 2025

The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, KS; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; U.S Myeloma Innovations Research Collaborative, Kansas City, KS. Electronic addres

Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only curative option for myelofibrosis (MF) but is often underutilized in patients aged ≥ 65 due to concerns about treatment-related toxicity.

Methods: We conducted a retrospective analysis of chronic-phase MF allo-HCT recipients using the publicly available CIBMTR P-5640 dataset (2008-2019). Key endpoints included overall survival (OS), disease-free survival (DFS), relapse, nonrelapse mortality (NRM), and graft-vs-host disease (GVHD)-related outcomes.

View Article and Find Full Text PDF

Ketamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability.

Am J Geriatr Psychiatry

August 2025

Mood Disorder and Psychopharmacology Unit (RS, JKT, CED, RSM), University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronnto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, ON, Canada. Electronic address: roger.mcintyre@

Ketamine has emerged as a promising treatment for major depression, though its efficacy and safety remain incompletely characterized in older adults. This systematic review synthesizes current evidence for ketamine in geriatric depression. A search of PubMed, EMBASE, and PsycINFO was conducted.

View Article and Find Full Text PDF